Search results
Results from the WOW.Com Content Network
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
The safety and efficacy of trastuzumab-containing combination therapies (with chemotherapy, hormone blockers, or lapatinib) for the treatment of metastatic breast cancer. [clarification needed] The overall hazard ratios (HR) for overall survival and progression free survival were 0.82 and 0.61, respectively.
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-induced diarrhea (CID). The trial ...
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via ...
In the advanced cancer setting, trastuzumab use in combination with chemotherapy can both delay cancer growth as well as improve the recipient's survival. [49] Pertuzumab may work synergistically with trastuzumab on the expanded EGFR family of receptors, although it is currently only standard of care for metastatic disease.
The association said that “one key question” taken up by the roundtable was whether ARIA was a temporary symptom of the new drug — much the way nausea and hair loss are side effects of ...
The House Ethics Committee’s report on former Rep. Matt Gaetz, R-Fla., includes evidence he paid women for sex, including one who was underage.